NRP1 and acute myeloid leukemia: CD33, also referred to as Siglec-3, is a transmembrane receptor expressed on cells of myeloid lineage that is expressed in more than 90% of patients with acute myeloid leukemia (AML).49 Therefore, it may be a potential target for the treatment of AML.